[Prostatic specific antigen in practice in 1997].
PSA (Prostate Specific Antigen) has modified the management of prostatic disease. Changes of PSA levels can be observed in many clinical circumstances other than cancer (endoscopic procedures, prostatitis, medications, etc.). Various methods have been proposed to increase the specificity of PSA in prostatic cancer, particularly when the PSA level is between 4 and 10 ng/ml: age-related PSA, PSA density, PSA velocity, freePSA. These methods allow more refined indications for transrectal biopsies of the prostate which provide the histological evidence essential for the diagnosis of cancer.
Salomon
L
L
Service d'Urologie, Hôpital Henri Mondor, Créteil.
Colombel
M
M
Patard
J J
JJ
Chopin
D
D
Abbou
C C
CC
D000328:Adult; D000367:Age Factors; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D015415:Biomarkers; D017430:Prostate-Specific Antigen
Le PSA en pratique en 1997.